| Autor: |
McCann TS; a Department of Pathology , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA., Sobral LM; a Department of Pathology , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA., Self C; b Department of Pediatrics , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA., Hsieh J; c Medical Scientist Training Program , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA., Sechler M; a Department of Pathology , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.; d Cancer Biology Program , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA., Jedlicka P; a Department of Pathology , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.; c Medical Scientist Training Program , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.; d Cancer Biology Program , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA. |
| Abstrakt: |
Introduction: Epigenetic mechanisms of gene regulatory control play fundamental roles in developmental morphogenesis, and, as more recently appreciated, are heavily implicated in the onset and progression of neoplastic disease, including cancer. Many epigenetic mechanisms are therapeutically targetable, providing additional incentive for understanding of their contribution to cancer and other types of neoplasia. Areas covered: The Jumonji-domain histone demethylase (JHDM) family exemplifies many of the above traits. This review summarizes the current state of knowledge of the functions and pharmacologic targeting of JHDMs in cancer and other neoplastic processes, with an emphasis on diseases affecting the pediatric population. Expert opinion: To date, the JHDM family has largely been studied in the context of normal development and adult cancers. In contrast, comparatively few studies have addressed JHDM biology in cancer and other neoplastic diseases of childhood, especially solid (non-hematopoietic) neoplasms. Encouragingly, the few available examples support important roles for JHDMs in pediatric neoplasia, as well as potential roles for JHDM pharmacologic inhibition in disease management. Further investigations of JHDMs in cancer and other types of neoplasia of childhood can be expected to both enlighten disease biology and inform new approaches to improve disease outcomes. |
